300601 Stock Overview
Shenzhen Kangtai Biological Products Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Shenzhen Kangtai Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥19.04 |
| 52 Week High | CN¥34.18 |
| 52 Week Low | CN¥12.93 |
| Beta | 0.90 |
| 11 Month Change | 4.27% |
| 3 Month Change | 32.41% |
| 1 Year Change | -36.28% |
| 33 Year Change | -72.56% |
| 5 Year Change | -62.37% |
| Change since IPO | -54.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300601 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -8.1% | -6.3% | -4.1% |
| 1Y | -36.3% | -18.6% | 3.8% |
Return vs Industry: 300601 underperformed the CN Biotechs industry which returned -19.7% over the past year.
Return vs Market: 300601 underperformed the CN Market which returned 1.9% over the past year.
Price Volatility
| 300601 volatility | |
|---|---|
| 300601 Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 300601's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300601's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,902 | Xiang Miao | www.biokangtai.com |
Shenzhen Kangtai Biological Products Co., Ltd. researches and develops, produces, and sells various types of human vaccines in China. Its marketed vaccines include SARS-COV-2 vaccines, HIB conjugate vaccines, 13-valent pneumococcal conjugate vaccines, recombinant hepatitis B vaccines, 23-valent pneumococcal polysaccharide vaccines, diphtheria tetanus acellular pertussis and haemophilus influenzae type b combined vaccines, cell-free whitebait b-type haemophilus influenzae combined vaccines, and measles and rubella combined vaccines.
Shenzhen Kangtai Biological Products Co., Ltd. Fundamentals Summary
| 300601 fundamental statistics | |
|---|---|
| Market cap | CN¥21.27b |
| Earnings (TTM) | CN¥515.35m |
| Revenue (TTM) | CN¥3.03b |
41.3x
P/E Ratio7.0x
P/S RatioIs 300601 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300601 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.03b |
| Cost of Revenue | CN¥645.50m |
| Gross Profit | CN¥2.39b |
| Other Expenses | CN¥1.87b |
| Earnings | CN¥515.35m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.46 |
| Gross Margin | 78.70% |
| Net Profit Margin | 17.00% |
| Debt/Equity Ratio | 21.8% |
How did 300601 perform over the long term?
See historical performance and comparison